Mainz, December 20, 2013 – – TRON is whishing all of its partners and friends happy holidays and a successful New Year 2014. The TRON labs and offices are closed December 23 through January 1.
Archive | News-Archiv-2013
Placenta-specific gene PLAC1 affirmed as possible new breast cancer target
Mainz, Germany, December 12, 2013 – A new study by TRON researchers has affirmed the role of the placenta-specific gene PLAC1 as a promising candidate for targeted breast cancer therapies. The findings by Wagner et al. have been published in the December issue of BMC Cancer.
TRON Seminar in Translational Oncology: Prof. Yardena Samuels
Mainz, December 12, 2013 – “The Genetics of Melanoma: Searching for New Therapeutic Targets” with Prof. Yardena Samuels – Weizmann Institute of Science, Rehovot, Israel
TRON Seminar in Translational Oncology: Prof. Gunther Hartmann
Mainz, December 3, 2013 – “RIG-I ligand therapies” with Prof. Dr. med. Gunther Hartmann – University Medical Center Bonn, Germany
TRON at MEDICA
Mainz, November 22, 2013 – As part of the state of Rhineland-Palatinate’s health research and technology exhibit at MEDICA, November 20-23, 2013 in Düsseldorf, Germany, TRON is presenting its research, mission and service offerings.
Novel approaches to molecular vaccines
Mainz, November 12, 2013 – Dr. Sebastian Kreiter, head of the TRON Immunotherapy Development Center, will present about novel approaches to molecular vaccines as part of the ESMO Symposium on Immuno-Oncology in Geneva.
November 13 “Ci3 Schaufenster” at TRON
Mainz, Germany, October 23, 2013 – As part of the „Ci3 Schaufenster“ event series, TRON invites the Ci3 partners as well as the interested public to an information evening on November 13 about the structure and work of TRON. A special focus will be put on the role of next-generation sequencing in biomarker identification and
New blueprint outlines a regulatory framework for novel “actively personalized” vaccines (“APVACs)
Mainz, October 17, 2013 – The Regulatory Research Group of the Association for Cancer Immunotherapy (CIMT-RRG) has published a blueprint for the development of “actively personalized” vaccines (APVACs). The proposal, published in the October issue of Nature Biotechnology, outlines how APVACs may be pursued within the existing regulatory framework of the European Union (EU).
Preclinical research at TRON identifies oncogene addiction as a promising strategy for treating leukaemia
Mainz, Germany, October 9, 2013 – TRON researchers together with scientists from the University Medical Center Mainz have tracked down the molecular mechanisms leading to one of the most common types of blood cancer, a disease called core binding factor acute myeloid leukaemia (CBF-AML). The results are now published in the journal EMBO Molecular Medicine.
Marketplace “Personalized Medicine Technologies”
Mainz, October 7, 2013 – At BIOTECHNICA 2013 in Hannover (October 8-10), TRON researchers Dr. Cedrik Britten and Dr. Valesca Boisguérin will present methods and platforms for personalized cancer diagnostics and therapeutics that are researched and developed at TRON.
New Cancer Targets Expert Meeting
Heidelberg, September 23, 2013 – At the New Cancer Targets Conference in Heidelberg, TRON founder and scientific director Ugur Sahin will address the path towards individualized immunotherapy. Sahin is one of 30 international speakers invited by the National Center for Tumor Diseases (NCT) Heidelberg.
Ci3 Cluster partners report project updates
Mainz, Germany, September 17, 2013 – Today, partners of the BMBF funded Cluster for Individualized ImmuneIntervention present their ongoing projects at Schloss Biebrich in Wiesbaden. The day-long event offers cluster partners the opportunity to network and provide project updates. As a Ci3 partner, TRON will participate with several short talks, posters and an information booth.
